Fig. 1.
MGMT promoter methylation status. Overall survival (A) and first‐line progression‐free survival (B) represented through Kaplan–Meier curves according to MGMT promoter methylation status in the Italian cohort. Patients with MGMT hypermethylation (blue) experienced worse median overall survival as compared with patients with low MGMT methylation (red) (A). MGMT promoter methylation values did not impact the progression‐free survival of patients treated with first‐line systemic treatment for advanced disease (B). Dotted lines indicate the median survival time. MGMT, O 6‐methylguanine‐DNA methyltransferase. [Colour figure can be viewed at wileyonlinelibrary.com]